A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
A phase 2/3 trial of Abemaciclib, Abiraterone acetate, Prednisone in prostate cancer, run by Eli Lilly and Company, active and no longer recruiting.
Overview
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer is a phase 2/3 interventional study registered as NCT03706365 by Eli Lilly and Company, with 393 participants enrolled, started 2018-11-26 and due to reach its primary completion in 2024-01-02. Interventions recorded: Abemaciclib, Placebo, Abiraterone acetate, Prednisone. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Shares Prednisone, Abemaciclib, Eli Lilly (incl. Loxo), Prostate cancer.
- TrialA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.
- TrialA Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Shares Prednisone, Abiraterone acetate, Prostate cancer.